Nevertheless, besides the known differences in clinicopathological features in breast cancer cases associated with germline BRCA1 or BRCA2 pathogenic variants9–12, there is a lack of evidence so far on whether the type of mutated gene may also lead to potential differences in breast cancer clinical behavior and outcomes. This evidence concerns the gene BRCA2 and breast carcinoma.